Phase I study with ONCOS-102 for the treatment of solid tumors - an evaluation of clinical response and exploratory analyses of immune markers.

T, Ranki; S, Pesonen; A, Hemminki; K, Partanen; K, Kairemo; T, Alanko; J, Lundin; N, Linder; R, Turkki; A, Ristimäki; E, Jäger; J, Karbach; C, Wahle; M, Kankainen; C, Backman; Euler M, von; E, Haavisto; T, Hakonen; R, Heiskanen; M, Jaderberg; J, Juhila; P, Priha; L, Suoranta; L, Vassilev; A, Vuolanto; T, Joensuu

doi:10.1186/s40425-016-0121-5

Public

Phase I study with ONCOS-102 for the treatment of solid tumors - an evaluation of clinical response and exploratory analyses of immune markers.

Shared by NobleBlocks on Mar 15, 2016 • 12:00 AM UTC

Authors:

Ranki T

Pesonen S

Hemminki A

Abstract

Background We conducted a phase I study with a granulocyte macrophage colony stimulating factor (GMCSF)-expressing oncolytic adenovirus, ONCOS-102, in patients with solid tumors refractory to available treatments. The objectives of the study were to determine the optimal dose for further use and to ...

Subject

Immunotherapy

Anti-tumor immunity

oncolytic adenovirus

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!